PCM
REGN icon

Prelude Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Prelude Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,000
Closed -$966K – 1772
2020
Q4 		$966K Hold
2,000
– – 0.02% 487
2020
Q3 		$1.12M Hold
2,000
– – 0.05% 254
2020
Q2 		$1.25M Buy
+2,000
New +$1.14M 0.07% 264
2015
Q3 		– Sell
-700
Closed -$357K – 1729
2015
Q2 		$357K Hold
700
– – 0.05% 399
2015
Q1 		$316K Buy
+700
New +$297K 0.04% 486

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prelude Capital Management's REGN Position: Q1 2026 in Review

Prelude Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 331 shares — an estimated $255K sold.

Prelude Capital Management first reported a position in REGN in Q2 2013 and held it in 34 quarters. The position peaked at $1.17M in Q2 2013. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Prelude Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 331 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $255K.
  • Prelude Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 34 quarters.
  • Prelude Capital Management's Regeneron Pharmaceuticals position peaked at $1.17M in Q2 2013.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.